文献速递自身免疫性与大疱性皮肤病

大疱性类天疱疮严重程度与BP180和BP230抗体水平:系统综述与荟萃分析

Bullous Pemphigoid Severity and Levels of Antibodies to BP180 and BP230: A Systematic Review and Meta-Analysis.
PubMed 文献 · JAMA Dermatol · 2024-01-01

该系统综述与荟萃分析纳入14项研究共1226例大疱性类天疱疮患者,评估抗BP180和抗BP230 IgG抗体水平与疾病严重程度的相关性。结果显示抗BP180抗体水平与BPDAI和ABSIS在基线、3个月和6个月随访时呈中度至强相关,而抗BP230抗体水平与疾病严重程度无关联。抗BP180抗体水平可能作为监测大疱性类天疱疮疾病严重程度的辅助工具。

要点

  • 抗BP180抗体水平与BPDAI和ABSIS在基线、3个月和6个月随访时呈中度至强相关。
  • 抗BP230抗体水平在诊断和随访时与BPDAI和ABSIS均无关联。
  • 抗BP180抗体水平可能作为监测大疱性类天疱疮疾病严重程度的辅助工具。

核心结论

  • 抗BP180自身抗体水平可能作为监测大疱性类天疱疮疾病严重程度和指导临床治疗的辅助工具。

研究设计与样本

  • 系统综述与荟萃分析,检索Cochrane Central Register of Controlled Trials、Embase和PubMed数据库从建库至2024年4月11日。
  • 纳入评估ELISA测定的抗BP180或抗BP230 IgG血清水平与按ABSIS或BPDAI评估的疾病严重程度之间相关性的研究,无语言或地域限制。
  • 最终纳入14项研究共1226例参与者,采用随机效应模型进行荟萃分析,并根据ELISA试剂盒制造商进行亚组分析。

主要发现

  • 抗BP180自身抗体水平与客观BPDAI在基线呈中度相关(r=0.56;95%CI,0.46-0.64),3个月随访时呈强相关(r=0.63;95%CI,0.39-0.79),6个月随访时呈中度相关(r=0.53;95%CI,0.25-0.72)。
  • 抗BP180自身抗体水平与ABSIS在基线呈中度相关(r=0.52;95%CI,0.39-0.62),3个月随访时呈强相关(r=0.62;95%CI,0.39-0.79),6个月随访时呈中度相关(r=0.53;95%CI,0.25-0.72)。
  • 抗BP230自身抗体水平在诊断和随访时与客观BPDAI和ABSIS均无关联。
  • 亚组分析发现使用不同ELISA试剂盒时结果相似。

临床怎么用

  • 临床可考虑将抗BP180抗体水平作为辅助工具,用于监测大疱性类天疱疮疾病严重程度和指导临床治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The correlation between serum levels of autoantibodies against bullous pemphigoid (BP) antigens 180 (BP180) and 230 (BP230) with BP disease severity is unclear. OBJECTIVE: To investigate the correlation of anti-BP180 and anti-BP230 immunoglobulin G (IgG) antibody levels with BP disease severity. DATA SOURCES: A search was performed of the Cochrane Central Register of Controlled Trials, Embase, and PubMed databases from their respective inception to April 11, 2024. STUDY SELECTION: Studies evaluating the correlation between serum levels of anti-BP180 or anti-BP230 IgG measured using enzyme-linked immunosorbent assay (ELISA) and disease severity assessed per the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) or BP Disease Area Index (BPDAI) were included. No language or geographic restrictions were imposed. Nearly 0.4% of initially identified studies met the selection criteria. DATA EXTRACTION AND SYNTHESIS: One researcher extracted data and another researcher confirmed data. The risk of bias was independently assessed by these researchers using the Quality Assessment of Diagnostic Accuracy Studies 2 tool, with discrepancies resolved by discussion with a third researcher. A random-effects model meta-analysis and a subgroup analysis were conducted based on the ELISA kit manufacturers. MAIN OUTCOMES AND MEASURES: Pooled correlation coefficients of antibody levels with ABSIS and BPDAI. RESULTS: In all, 14 studies with 1226 participants were analyzed. The risk of bias of included studies was generally low. The meta-analysis found anti-BP180 autoantibody levels showed moderate correlation with objective BPDAI (r = 0.56; 95% CI, 0.46-0.64) at baseline, strong correlation (r = 0.63; 95% CI, 0.39-0.79) at 3-month follow-up, and moderate correlation (r = 0.53; 95% CI, 0.25-0.72) at 6-month follow-up. Anti-BP180 autoantibody levels also showed moderate correlation (r = 0.52; 95% CI, 0.39-0.62) with ABSIS at baseline, strong correlation (r = 0.62; 95% CI, 0.39-0.79) at 3-month follow-up, and moderate correlation (r = 0.53; 95% CI, 0.25-0.72) at 6-month follow-up. By contrast, anti-BP230 autoantibody levels showed no association with objective BPDAI and ABSIS at diagnosis and follow-up. The subgroup analysis found similar results when using different ELISA kits. CONCLUSIONS AND RELEVANCE: The findings of this systematic review and meta-analysis indicated that anti-BP180 autoantibody levels may serve as an adjunctive tool for monitoring BP disease severity and guiding clinical care for patients with BP.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Chou PY, Yu CL, Wen CN, et al. Bullous Pemphigoid Severity and Levels of Antibodies to BP180 and BP230: A Systematic Review and Meta-Analysis. JAMA Dermatol. 2024. PMID: 39356527. doi:10.1001/jamadermatol.2024.3425

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。